comparemela.com

Page 3 - Sergio Traversa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

New yorkUnited statesTim mccarthyCedric ogormanMaged shenoudaSergio traversaRelmada therapeutics incSecurities exchangeRelmada therapeuticsChief executive officerChief financial officerCedrico gormanChief medical officerJefferies inaugural biotechNeuro summitPrivate securities litigation reform act

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

CORAL GABLES, Fla., Aug. 8, 2023 /PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update

Sergio traversaTim mccarthyRelmada therapeutics incCorporate communicationsClinical research programPrnewswire relmada therapeutics incSecurities exchangeChief executiveAnticipated milestonesMonths ended juneRelmada therapeuticsPrivate securities litigation reform actSecurities actSecurities exchange actConsolidated statementsNation world

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

Sergio traversaTim mccarthySecurities exchangeCorporate communicationsPrnewswire relmada therapeutics incClinical research programRelmada therapeutics incChief executiveCorporate highlightsAnticipated milestonesMonths ended juneRelmada therapeuticsPrivate securities litigation reform actSecurities actSecurities exchange actConsolidated statements

Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

Sergio traversaCedric ogormanMaged shenoudaTim mccarthySecurities exchangeGoldman sachsPrnewswire relmada therapeutics incReliance clinical research programRelmada therapeutics incChief executive officerChief financial officerCedrico gormanChief medical officerGoldman sachs global healthcare conferenceDana pointRelmada therapeutics

Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

New yorkUnited statesMaged shenoudaTim mccarthyCedric ogormanSergio traversaRelmada therapeutics incReliance clinical research programPrnewswire relmada therapeutics incSecurities exchangeChief executive officerChief financial officerCedrico gormanChief medical officerGlobal healthcare conferenceGlobal healthcare

vimarsana © 2020. All Rights Reserved.